ABSTRACT. Purpose: We report on thè combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age-related macular degeneration (AMD). Methods: The clinical interventional case-series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5 ±1. 8 mono-injec-tions of bevacizumab (1.5 mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. AH patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. AH patients were re-examined at 2-3 months after thè intervention. Results: Visual acuity improved significantly (p = 0.03) from 0.80 ± 0.40 logMAR prior to thè combined injection to 0.65 ± 0.42 logMAR at 3 months after thè injection. An improvement of > 1 Snellen line was found in eight sub-jects, an increase of > 2 lines in five subjects, and an improvement of > 3 lines in two subjects. One patient lost 1 line and one patient lost 3 lines. Central retinal thickness decreased significantly from 272 ± 62 ^m to 220 ± 47 firn (p = 0.03). At thè 6-month follow-up examination, centrai retinal thickness had increased again to 319 ± 142 fan, which was not significantly (p = 0.30) different from baseline measurements. Conclusions: The combined intravitreal application of bevacizumab and triam-cinolone may temporarily be helpful in thè treatment of exudative AMD if previous intravitreal bevacizumab mono-injections bave failed to improve vision and reduce macular oedema.

COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION

LIBONDI, Teodosio;
2009

Abstract

ABSTRACT. Purpose: We report on thè combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age-related macular degeneration (AMD). Methods: The clinical interventional case-series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5 ±1. 8 mono-injec-tions of bevacizumab (1.5 mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. AH patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. AH patients were re-examined at 2-3 months after thè intervention. Results: Visual acuity improved significantly (p = 0.03) from 0.80 ± 0.40 logMAR prior to thè combined injection to 0.65 ± 0.42 logMAR at 3 months after thè injection. An improvement of > 1 Snellen line was found in eight sub-jects, an increase of > 2 lines in five subjects, and an improvement of > 3 lines in two subjects. One patient lost 1 line and one patient lost 3 lines. Central retinal thickness decreased significantly from 272 ± 62 ^m to 220 ± 47 firn (p = 0.03). At thè 6-month follow-up examination, centrai retinal thickness had increased again to 319 ± 142 fan, which was not significantly (p = 0.30) different from baseline measurements. Conclusions: The combined intravitreal application of bevacizumab and triam-cinolone may temporarily be helpful in thè treatment of exudative AMD if previous intravitreal bevacizumab mono-injections bave failed to improve vision and reduce macular oedema.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11591/228322
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact